To the Editor:

We read the article "Radiation for glioblastoma in the era of COVID-19: Patient selection and hypofractionation to maximize benefit and minimize risk" with great interest.[@bib1] We congratulate the authors for drafting guidance for selecting patients with glioblastoma who would benefit from hypofractionated radiation therapy (RT) in the era of coronavirus disease 2019 (COVID-19). The authors suggest that elderly patients (aged ≥65 years) with glioblastoma should strongly be considered for hypofractionated RT regimens of 40 Gy in 15 fractions.[@bib2] For patients with very poor performance status (PS; Karnofsky PS \[KPS\] \< 50 or Eastern Cooperative Oncology Group \[ECOG\] score 3-4), the palliative regimens the authors recommended were of either 34 Gy in 10 fractions, 25 Gy in 5 fractions, or temozolomide with the omission of RT, and each regimen was supported by prospective trial data.[@bib3], [@bib4], [@bib5]

We suggest a cautious interpretation of the recommendations for a very poor PS (KPS \< 50) subset. We want to highlight that these referenced landmark studies did not represent patients with very poor PS. The International Atomic Energy Agency trial included patients aged 50 years with a KPS of 50 to 70, elderly and frail patients aged 65 years and a KPS of 50 to 70, and elderly patients aged 65 years and a KPS of 80 to 100. With a median overall survival of 7.9 months with 25 Gy in 5 fractions compared with a median overall survival of 6.4 months with hypofractionated RT of 40 Gy in 15 fractions, there was no survival difference.[@bib3]

Similarly, the Nordic trial studied patients aged ≥60 years with World Health Organiozation performance scores of 0 to 2 (even if neurologic deficits showed a performance score of 3).[@bib4] Importantly, 78% of patients in this study had an ECOG score of 0 to 1. Although temozolomide alone is an appropriate option for individuals aged \>60 years with an ECOG score of 0 to 2, its use in the current pandemic requires careful attention.[@bib4] Patients prescribed temozolomide alone had a higher risk of neutropenia (12%), thrombocytopenia (21%), and infection (19%).[@bib4] In the current scenario, temozolomide induces immunosuppression and could increase the risk of contracting COVID-19. Thus, the recommendation of its use in patients with poor PS (KPS \< 50) deserves extreme caution.[@bib4]

We recommend the best supportive care or an ultra-short course of International Atomic Energy Agency regimens, which may serve as a better option for patients with poor PS in the current COVID-19 times.
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